Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
852A in Hematologic Malignancies
NCT00276159Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2006
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 852A in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), multiple myeloma (MM), sponsored by Masonic Cancer Center. Started Jan 2006; status: terminated.
02
Drugs
852A
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00276159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276159.